Common Side Effects of Eteplirsen in DMD Patients
Eteplirsen (Exondys 51), approved for Duchenne muscular dystrophy (DMD) in patients with confirmed exon 51 skipping mutations, causes side effects mainly from its intravenous administration. The most frequent ones, reported in at least 10% of patients in clinical trials, include rash, fever, contact dermatitis (from IV catheter), vomiting, and nausea.[1][2]
Patients often experience injection-site reactions like pain, erythema, and swelling, along with flu-like symptoms such as headache, joint pain, and fatigue. These typically occur shortly after infusion and may decrease over time with slower infusion rates.[1]
How Often Do These Side Effects Happen?
In pivotal trials (Studies 201, 202, and 301), over 60% of patients had at least one treatment-related adverse event. Specific rates:
- Rash: 17-29%
- Fever: 25-35%
- Vomiting: 20-29%
- Nausea: 15-20%
- Contact dermatitis: 15-25%
Most are mild to moderate and do not lead to discontinuation, though monitoring for hypersensitivity is required.[1][3]
Why Do These Side Effects Occur?
Eteplirsen is an antisense oligonucleotide that binds RNA to enable exon skipping. Side effects stem from immune activation (cytokine release causing fever and flu-like symptoms) and direct skin irritation from weekly IV delivery. Pre-medication with antihistamines or steroids can reduce rash and fever incidence.[2][4]
Serious Risks and What to Watch For
While common effects are manageable, rare serious issues include anaphylaxis, angioedema, and severe rash requiring hospitalization (less than 5% of cases). Decreased platelet counts and elevated liver enzymes have also occurred, prompting baseline blood tests before starting and periodic checks.[1][3]
Long-term data from open-label extensions show side effects persist but rarely worsen; no new safety signals emerged after years of use.[4]
How Does Eteplirsen Compare to Other DMD Drugs?
| Drug | Common Side Effects | Key Difference |
|------|----------------------|---------------|
| Eteplirsen | Rash, fever, vomiting (mostly mild) | High rate of skin reactions from IV use |
| Golodirsen (Vyondys 53) | Similar: fever (41%), headache (29%), rash | Slightly higher fever incidence |
| Viltolarsen (Viltepso) | Vomiting (41%), fever (27%), fall (27%) | More balance issues, fewer skin reactions |
| Deflazacort (steroid) | Weight gain, Cushingoid features, irritability | Systemic effects vs. eteplirsen's infusion-localized |
Eteplirsen's profile is comparable to other exon-skipping therapies but milder than steroids.[2][5]
Patient Tips for Managing Side Effects
Infuse over 2-4 hours to minimize reactions; start slower if needed. Use topical steroids for rash and antiemetics for nausea. Report persistent fever or breathing issues immediately. FDA labeling recommends avoiding live vaccines during treatment.[1][3]
[1]: FDA Exondys 51 Label
[2]: Sarepta Therapeutics Prescribing Information
[3]: ClinicalTrials.gov Study 301 Results
[4]: NEJM 2017 Eteplirsen Trial
[5]: Drugs.com DMD Treatment Comparison